PVLA
The table below shows Palvella Therapeutics, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$10.86M | -$6.77M | -$1.10M | -$11.00M | -$22.64M | -$12.14M |
| Capital expenditure | - | - | $0.00 | $48.00K | $389.00K | $28.00K |
| Investing cash flow | -$55.44M | $0.00 | $9.00M | $11.90M | -$16.95M | -$28.00K |
| Dividends paid | - | - | - | - |
Palvella Therapeutics, Inc. reported operating cash flow of -$25.01M for fiscal year 2025. That is down 130.7% from -$10.84M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$15.06K (FY 2014) to -$25.01M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $214.73M | -$1.20M | $0.00 | $0.00 | $6.56M | $9.69M |